Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Gemcitabine, and Radiation Therapy for Muscle-Invasive Bladder Cancer
NCT02621151Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Aug 2016
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Urothelial cancer of the bladder (UC), sponsored by NYU Langone Health. Primary endpoint: Bladder-intact Disease-free Survival at 2 years. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
Urothelial cancer of the bladder (UC)
Beyond the preview
Go deeper on NCT02621151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621151.